Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 26 03 2022
accepted: 14 06 2022
revised: 13 06 2022
pubmed: 6 7 2022
medline: 14 10 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

Increased serum levels of neurofilament light chain (sNFL), a biomarker of neuroaxonal damage, have been reported in patients with Covid-19. We aimed at investigating whether sNFL is increased in Covid-19 patients without major neurological manifestations, is associated with disease severity, respiratory and routine blood parameters, and changes longitudinally in the short term. sNFL levels were measured with single molecule array (Simoa) technology in 57 hospitalized Covid-19 patients without major neurological manifestations and in 30 neurologically healthy controls. Patients were evaluated for PaO2/FiO2 ratio on arterial blood gas, Brescia Respiratory Covid Severity Scale (BRCSS), white blood cell counts, serum C-reactive protein (CRP), plasma D-dimer, plasma fibrinogen, and serum creatinine at admission. In 20 patients, NFL was also measured on serum samples obtained at a later timepoint during the hospital stay. Covid-19 patients had higher baseline sNFL levels compared to controls, regardless of disease severity. Baseline sNFL correlated with serum CRP and plasma D-dimer in patients with mild disease, but was not associated with measures of respiratory impairment. Longitudinal sNFL levels tended to be higher than baseline ones, albeit not significantly, and correlated with serum CRP and plasma D-dimer. The PaO2/FiO2 ratio was not associated with longitudinal sNFL, whereas BRCSS only correlated with longitudinal sNFL variation. We provide neurochemical evidence of subclinical axonal damage in Covid-19 also in the absence of major neurological manifestations. This is apparently not fully explained by hypoxic injury; rather, systemic inflammation might promote this damage. However, a direct neurotoxic effect of SARS-CoV-2 cannot be excluded.

Sections du résumé

BACKGROUND BACKGROUND
Increased serum levels of neurofilament light chain (sNFL), a biomarker of neuroaxonal damage, have been reported in patients with Covid-19. We aimed at investigating whether sNFL is increased in Covid-19 patients without major neurological manifestations, is associated with disease severity, respiratory and routine blood parameters, and changes longitudinally in the short term.
METHODS METHODS
sNFL levels were measured with single molecule array (Simoa) technology in 57 hospitalized Covid-19 patients without major neurological manifestations and in 30 neurologically healthy controls. Patients were evaluated for PaO2/FiO2 ratio on arterial blood gas, Brescia Respiratory Covid Severity Scale (BRCSS), white blood cell counts, serum C-reactive protein (CRP), plasma D-dimer, plasma fibrinogen, and serum creatinine at admission. In 20 patients, NFL was also measured on serum samples obtained at a later timepoint during the hospital stay.
RESULTS RESULTS
Covid-19 patients had higher baseline sNFL levels compared to controls, regardless of disease severity. Baseline sNFL correlated with serum CRP and plasma D-dimer in patients with mild disease, but was not associated with measures of respiratory impairment. Longitudinal sNFL levels tended to be higher than baseline ones, albeit not significantly, and correlated with serum CRP and plasma D-dimer. The PaO2/FiO2 ratio was not associated with longitudinal sNFL, whereas BRCSS only correlated with longitudinal sNFL variation.
CONCLUSIONS CONCLUSIONS
We provide neurochemical evidence of subclinical axonal damage in Covid-19 also in the absence of major neurological manifestations. This is apparently not fully explained by hypoxic injury; rather, systemic inflammation might promote this damage. However, a direct neurotoxic effect of SARS-CoV-2 cannot be excluded.

Identifiants

pubmed: 35781535
doi: 10.1007/s00415-022-11233-5
pii: 10.1007/s00415-022-11233-5
pmc: PMC9252542
doi:

Substances chimiques

Biomarkers 0
Neurofilament Proteins 0
Fibrinogen 9001-32-5
C-Reactive Protein 9007-41-4
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5691-5701

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Références

Misra S et al (2021) Frequency of neurologic manifestations in COVID-19: a systematic review and meta-analysis. Neurology 97(23):e2269–e2281. https://doi.org/10.1212/WNL.0000000000012930
doi: 10.1212/WNL.0000000000012930 pubmed: 34635561
Oxley TJ et al (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382(20):e60. https://doi.org/10.1056/NEJMc2009787
doi: 10.1056/NEJMc2009787 pubmed: 32343504
Nalbandian A et al (2021) Post-acute COVID-19 syndrome. Nat Med 27(4):601–615. https://doi.org/10.1038/s41591-021-01283-z
doi: 10.1038/s41591-021-01283-z pubmed: 33753937 pmcid: 8893149
Johansson A, Mohamed MS, Moulin TC, Schioth HB (2021) Neurological manifestations of COVID-19: a comprehensive literature review and discussion of mechanisms. J Neuroimmunol 358:577658. https://doi.org/10.1016/j.jneuroim.2021.577658
doi: 10.1016/j.jneuroim.2021.577658 pubmed: 34304141 pmcid: 8272134
Khalil M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577–589. https://doi.org/10.1038/s41582-018-0058-z
doi: 10.1038/s41582-018-0058-z pubmed: 30171200
Ameres M et al (2020) Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. J Neurol 267(12):3476–3478. https://doi.org/10.1007/s00415-020-10050-y
doi: 10.1007/s00415-020-10050-y pubmed: 32647900 pmcid: 7345451
Kanberg N et al (2020) Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology 95(12):e1754–e1759. https://doi.org/10.1212/WNL.0000000000010111
doi: 10.1212/WNL.0000000000010111 pubmed: 32546655
Hay M et al (2021) Serum neurofilament light is elevated in COVID-19 positive adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness. Cardiol Cardiovasc Med 5(5):551–565. https://doi.org/10.26502/fccm.92920221
doi: 10.26502/fccm.92920221 pubmed: 34708189 pmcid: 8547787
Sutter R et al (2021) Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without Coronavirus Disease 2019. Ann Neurol 89(3):610–616. https://doi.org/10.1002/ana.26004
doi: 10.1002/ana.26004 pubmed: 33377539
Aamodt AH et al (2021) Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. J Neurol 268(10):3574–3583. https://doi.org/10.1007/s00415-021-10517-6
doi: 10.1007/s00415-021-10517-6 pubmed: 33743046 pmcid: 7980743
De Lorenzo R et al (2021) Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. J Neurol 268(12):4436–4442. https://doi.org/10.1007/s00415-021-10595-6
doi: 10.1007/s00415-021-10595-6 pubmed: 33973106 pmcid: 8108733
Frontera JA et al (2022) Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer’s dementia. Alzheimers Dement 18(5):899–910. https://doi.org/10.1002/alz.12556
doi: 10.1002/alz.12556 pubmed: 35023610 pmcid: 9011610
Prudencio M et al (2021) Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Sci Transl Med 13:602. https://doi.org/10.1126/scitranslmed.abi7643
doi: 10.1126/scitranslmed.abi7643
Virhammar J et al (2021) Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol 28(10):3324–3331. https://doi.org/10.1111/ene.14703
doi: 10.1111/ene.14703 pubmed: 33369818 pmcid: 8518988
Paterson RW et al (2021) Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Commun 3(3):fcab099. https://doi.org/10.1093/braincomms/fcab099
doi: 10.1093/braincomms/fcab099 pubmed: 34396099 pmcid: 8194666
Bozzetti S et al (2021) Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae? Immunol Res 69(6):553–557. https://doi.org/10.1007/s12026-021-09220-5
doi: 10.1007/s12026-021-09220-5 pubmed: 34363587 pmcid: 8346772
Kanberg N et al (2021) Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 70:103512. https://doi.org/10.1016/j.ebiom.2021.103512
doi: 10.1016/j.ebiom.2021.103512 pubmed: 34333238 pmcid: 8320425
Piva S et al (2020) Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care 58:29–33. https://doi.org/10.1016/j.jcrc.2020.04.004
doi: 10.1016/j.jcrc.2020.04.004 pubmed: 32330817 pmcid: 7194649
Gattinoni L, Pesenti A, Matthay M (2018) Understanding blood gas analysis. Intensive Care Med 44(1):91–93. https://doi.org/10.1007/s00134-017-4824-y
doi: 10.1007/s00134-017-4824-y pubmed: 28497267
Teunissen CE et al (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73(22):1914–1922. https://doi.org/10.1212/WNL.0b013e3181c47cc2
doi: 10.1212/WNL.0b013e3181c47cc2 pubmed: 19949037 pmcid: 2839806
Chung HY, Neu C, Wickel J, Kuckertz SL, Coldewey SM (2021) Neurofilament light chain in patients with COVID-19 and bacterial pneumonia. Ann Neurol 90(1):174–175. https://doi.org/10.1002/ana.26135
doi: 10.1002/ana.26135 pubmed: 34036618 pmcid: 8222870
Moseby-Knappe M et al (2019) Serum neurofilament light chain for prognosis of outcome after cardiac arrest. JAMA Neurol 76(1):64–71. https://doi.org/10.1001/jamaneurol.2018.3223
doi: 10.1001/jamaneurol.2018.3223 pubmed: 30383090
Grasselli G et al (2020) Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med 8(12):1201–1208. https://doi.org/10.1016/S2213-2600(20)30370-2
doi: 10.1016/S2213-2600(20)30370-2 pubmed: 32861276 pmcid: 7834127
Ehler J et al (2019) The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy—a prospective, pilot observational study. PLoS ONE 14(1):e0211184. https://doi.org/10.1371/journal.pone.0211184
doi: 10.1371/journal.pone.0211184 pubmed: 30677080 pmcid: 6345472
Fong TG et al (2020) Association of plasma neurofilament light with postoperative delirium. Ann Neurol 88(5):984–994. https://doi.org/10.1002/ana.25889
doi: 10.1002/ana.25889 pubmed: 32881052 pmcid: 7581557
Pilotto A et al (2021) Long-term neurological manifestations of COVID-19: prevalence and predictive factors. Neurol Sci 42(12):4903–4907. https://doi.org/10.1007/s10072-021-05586-4
doi: 10.1007/s10072-021-05586-4 pubmed: 34523082 pmcid: 8439956
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ (2021) 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8(5):416–427. https://doi.org/10.1016/S2215-0366(21)00084-5
doi: 10.1016/S2215-0366(21)00084-5 pubmed: 33836148 pmcid: 8023694
Yang AC et al (2021) Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature 595(7868):565–571. https://doi.org/10.1038/s41586-021-03710-0
doi: 10.1038/s41586-021-03710-0 pubmed: 34153974 pmcid: 8400927
Ferrucci R et al (2021) Long-lasting cognitive abnormalities after COVID-19. Brain Sci 11(2):2. https://doi.org/10.3390/brainsci11020235
doi: 10.3390/brainsci11020235
Meinhardt J et al (2021) Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 24(2):168–175. https://doi.org/10.1038/s41593-020-00758-5
doi: 10.1038/s41593-020-00758-5 pubmed: 33257876
Wan D et al (2021) Neurological complications and infection mechanism of SARS-COV-2. Signal Transduct Target Ther 6(1):406. https://doi.org/10.1038/s41392-021-00818-7
doi: 10.1038/s41392-021-00818-7 pubmed: 34815399 pmcid: 8609271
Gafson AR et al (2020) Neurofilaments: neurobiological foundations for biomarker applications. Brain 143(7):1975–1998. https://doi.org/10.1093/brain/awaa098
doi: 10.1093/brain/awaa098 pubmed: 32408345 pmcid: 7363489

Auteurs

Federico Verde (F)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy. f.verde@auxologico.it.
Department of Pathophysiology and Transplantation and "Dino Ferrari" Center, Università degli Studi di Milano, Milan, Italy. f.verde@auxologico.it.

Ilaria Milone (I)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy.

Ilaria Bulgarelli (I)

Department of Laboratory Medicine, Laboratory of Clinical Chemistry, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Silvia Peverelli (S)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy.

Claudia Colombrita (C)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy.

Alessio Maranzano (A)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy.
Università degli Studi di Milano, Neurology Residency Program, Milan, Italy.

Narghes Calcagno (N)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy.
Università degli Studi di Milano, Neurology Residency Program, Milan, Italy.

Nicola Ticozzi (N)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy.
Department of Pathophysiology and Transplantation and "Dino Ferrari" Center, Università degli Studi di Milano, Milan, Italy.

Giovanni Battista Perego (GB)

Department of Cardiology, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Gianfranco Parati (G)

Department of Cardiology, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Department of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Milan, Italy.

Erminio Torresani (E)

Department of Laboratory Medicine, Laboratory of Clinical Chemistry, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Antonia Ratti (A)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy.
Department of Medical Biotechnologies and Translational Medicine, Università degli Studi di Milano, Milan, Italy.

Vincenzo Silani (V)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia, 20, 20149, Milan, Italy.
Department of Pathophysiology and Transplantation and "Dino Ferrari" Center, Università degli Studi di Milano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH